Company: LNAI
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001731122-25-000765
Chunk: 105

Company: Lunai Bioworks Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 8
Chunk 105
---
 the Company will be achieved.

Our Business

Renovaro
Inc. operates through two subsidiaries, Renovaro Biosciences and Renovaro Cube. Renovaro Cube refers to Renovaro Cube Intl. Ltd. (formerly
known as GediCube Intl. Ltd.) and its wholly owned subsidiaries GediCube, B.V. and Grace Systems B.V., which were acquired on February
13, 2024.

Renovaro Biosciences Overview

Renovaro
Biosciences is a biotechnology company intending, if the necessary funding is obtained, to develop advanced allogeneic cell and gene therapies
to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers,
and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. As a result of our
acquisition of GEDi Cube Intl Ltd. on February 13, 2024, we have shifted the Company’s primary focus and resources to the development
of the Renovaro Cube technologies.

Therapeutic Technologies

Renovaro Biosciences aims to train
the immune system to allow a person to better fight diseases through allogeneic cell and/or gene therapy. Our vision is for a world with
healthy longevity, and free from toxic chemotherapy, for those with cancer and other serious diseases. Renovaro Biosciences will seek
to leverage general principles and advances in the knowledge of the immune response to engineer cells with enhanced attributes to promote
the recognition and elimination of disease cells.

Allogeneic Cell Therapy 

The strategic benefit of the allogeneic
cell therapy technologies is to potentially allow for the manufacture of large, “off-the-shelf” banks of therapeutic cells
that are readily available on demand by healthcare professionals, to potentially decrease the time between diagnosis and treatment.

In certain treatments (e.g., HIV
and cancer), cells taken from healthy donors are engineered to introduce signaling molecules that are designed to enhance the ability
of specific immune cells to recognize diseased cells, and to help recruit other cells that will destroy cancer or virus infected cells.

24

Gene Therapy

Renovaro Biosciences may also seek
to explore various approaches for gene therapy design elements to potentially eliminate virus-infected or cancer cells by the modulation
of the patient’s immune system. Upon injecting into the patients, these genetically engineered allogeneic cells have little to no
risk of passing those modifications to the patient